It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

Key updates in the health sector have emerged, with AstraZeneca facing disappointment in a breast cancer drug trial. The ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...